Tolerability of Bisoprolol on Domiciliary Spirometry in COPD

Sunny Jabbal, Brian J. Lipworth (Lead / Corresponding author)

Research output: Contribution to journalArticle

82 Downloads (Pure)

Abstract

We investigated if serial domiciliary measures of spirometry were sensitive at detecting subtle effects of beta-2 blockade associated with bisoprolol in (n = 17) patients with COPD. After a two-week run in on inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA): beclometasone/formoterol 100/6 µg, patients' started additional a long acting muscarinic receptor antagonist: (LAMA) Tiotropium 18 µg, with concomitant weekly dose titration of bisoprolol: 1.25-2.5-5 mg. After a further week of bisoprolol 5 mg, they were stepped back down to (ICS/LABA) for one week. Mean age was 64 years, mean FEV1 52% predicted, and mean FEV1/FVC ratio of 0.46. Compared to baseline am FEV1 of 1.38 L (95% CI 1.14-1.61 L), both ICS/LABA/LAMA and ICS/LABA in conjunction with bisoprolol showed statistically significant mean falls of 100 ml (1.28 L, 95% CI 1.03-1.53 L), and 120 ml, respectively (1.26 L, 95% CI 1.01-1.51 L); equalling and exceeding the MCID of 100 ml, respectively. These changes were disconnected from symptoms, reliever use and oxygen saturation.

Original languageEnglish
Pages (from-to)11-14
Number of pages4
JournalLung
Volume196
Issue number1
Early online date14 Oct 2017
DOIs
Publication statusE-pub ahead of print - 14 Oct 2017

Fingerprint

Bisoprolol
Spirometry
Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Muscarinic Antagonists
Muscarinic Receptors
Beclomethasone
Oxygen

Keywords

  • COPD
  • Spirometry
  • FEV1
  • FEV6
  • Beta blocker

Cite this

@article{ab01b0750f624404a1cf098957d9f8b2,
title = "Tolerability of Bisoprolol on Domiciliary Spirometry in COPD",
abstract = "We investigated if serial domiciliary measures of spirometry were sensitive at detecting subtle effects of beta-2 blockade associated with bisoprolol in (n = 17) patients with COPD. After a two-week run in on inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA): beclometasone/formoterol 100/6 µg, patients' started additional a long acting muscarinic receptor antagonist: (LAMA) Tiotropium 18 µg, with concomitant weekly dose titration of bisoprolol: 1.25-2.5-5 mg. After a further week of bisoprolol 5 mg, they were stepped back down to (ICS/LABA) for one week. Mean age was 64 years, mean FEV1 52{\%} predicted, and mean FEV1/FVC ratio of 0.46. Compared to baseline am FEV1 of 1.38 L (95{\%} CI 1.14-1.61 L), both ICS/LABA/LAMA and ICS/LABA in conjunction with bisoprolol showed statistically significant mean falls of 100 ml (1.28 L, 95{\%} CI 1.03-1.53 L), and 120 ml, respectively (1.26 L, 95{\%} CI 1.01-1.51 L); equalling and exceeding the MCID of 100 ml, respectively. These changes were disconnected from symptoms, reliever use and oxygen saturation.",
keywords = "COPD, Spirometry, FEV1, FEV6, Beta blocker",
author = "Sunny Jabbal and Lipworth, {Brian J.}",
note = "The study was partially funded by TENOVUS Scotland (Grant No. T12/28) as well as from existing departmental unrestricted grant funds.",
year = "2017",
month = "10",
day = "14",
doi = "10.1007/s00408-017-0061-y",
language = "English",
volume = "196",
pages = "11--14",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer Verlag",
number = "1",

}

Tolerability of Bisoprolol on Domiciliary Spirometry in COPD. / Jabbal, Sunny; Lipworth, Brian J. (Lead / Corresponding author).

In: Lung, Vol. 196, No. 1, 14.10.2017, p. 11-14.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tolerability of Bisoprolol on Domiciliary Spirometry in COPD

AU - Jabbal, Sunny

AU - Lipworth, Brian J.

N1 - The study was partially funded by TENOVUS Scotland (Grant No. T12/28) as well as from existing departmental unrestricted grant funds.

PY - 2017/10/14

Y1 - 2017/10/14

N2 - We investigated if serial domiciliary measures of spirometry were sensitive at detecting subtle effects of beta-2 blockade associated with bisoprolol in (n = 17) patients with COPD. After a two-week run in on inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA): beclometasone/formoterol 100/6 µg, patients' started additional a long acting muscarinic receptor antagonist: (LAMA) Tiotropium 18 µg, with concomitant weekly dose titration of bisoprolol: 1.25-2.5-5 mg. After a further week of bisoprolol 5 mg, they were stepped back down to (ICS/LABA) for one week. Mean age was 64 years, mean FEV1 52% predicted, and mean FEV1/FVC ratio of 0.46. Compared to baseline am FEV1 of 1.38 L (95% CI 1.14-1.61 L), both ICS/LABA/LAMA and ICS/LABA in conjunction with bisoprolol showed statistically significant mean falls of 100 ml (1.28 L, 95% CI 1.03-1.53 L), and 120 ml, respectively (1.26 L, 95% CI 1.01-1.51 L); equalling and exceeding the MCID of 100 ml, respectively. These changes were disconnected from symptoms, reliever use and oxygen saturation.

AB - We investigated if serial domiciliary measures of spirometry were sensitive at detecting subtle effects of beta-2 blockade associated with bisoprolol in (n = 17) patients with COPD. After a two-week run in on inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA): beclometasone/formoterol 100/6 µg, patients' started additional a long acting muscarinic receptor antagonist: (LAMA) Tiotropium 18 µg, with concomitant weekly dose titration of bisoprolol: 1.25-2.5-5 mg. After a further week of bisoprolol 5 mg, they were stepped back down to (ICS/LABA) for one week. Mean age was 64 years, mean FEV1 52% predicted, and mean FEV1/FVC ratio of 0.46. Compared to baseline am FEV1 of 1.38 L (95% CI 1.14-1.61 L), both ICS/LABA/LAMA and ICS/LABA in conjunction with bisoprolol showed statistically significant mean falls of 100 ml (1.28 L, 95% CI 1.03-1.53 L), and 120 ml, respectively (1.26 L, 95% CI 1.01-1.51 L); equalling and exceeding the MCID of 100 ml, respectively. These changes were disconnected from symptoms, reliever use and oxygen saturation.

KW - COPD

KW - Spirometry

KW - FEV1

KW - FEV6

KW - Beta blocker

U2 - 10.1007/s00408-017-0061-y

DO - 10.1007/s00408-017-0061-y

M3 - Article

VL - 196

SP - 11

EP - 14

JO - Lung

JF - Lung

SN - 0341-2040

IS - 1

ER -